Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Accumulated Expenses (2016 - 2025)

China Pharma Holdings' Accumulated Expenses history spans 16 years, with the latest figure at $350643.0 for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 41.87% year-over-year to $350643.0; the TTM value through Dec 2025 reached $350643.0, up 41.87%, while the annual FY2025 figure was $350643.0, 41.87% up from the prior year.
  • Accumulated Expenses reached $350643.0 in Q4 2025 per CPHI's latest filing, up from $170426.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.3 million in Q3 2024 to a low of $110387.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $261330.0, with a median of $198550.0 recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: soared 949.15% in 2024, then plummeted 86.43% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $298452.0 in 2021, then surged by 35.64% to $404807.0 in 2022, then decreased by 26.18% to $298829.0 in 2023, then dropped by 17.29% to $247159.0 in 2024, then surged by 41.87% to $350643.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Accumulated Expenses are $350643.0 (Q4 2025), $170426.0 (Q3 2025), and $191293.0 (Q2 2025).